No — combining oxycodone with benzodiazepines (such as alprazolam, diazepam, or lorazepam) is not safe and carries a serious risk of severe respiratory depression, sedation, and fatal overdose. The FDA has issued a black box warning for this combination, and the agencies estimates that co-prescription of opioids and benzodiazepines is associated with a 10-fold increase in overdose risk compared to opioid use alone. If you are currently taking both medications, do not stop either drug abruptly—instead, contact your doctor or pharmacist immediately to discuss safer alternatives.
In 2016, the U.S. Food and Drug Administration strengthened its warning on the combination of opioids and benzodiazepines, adding a black box warning to both drug classes. This is the agency's most serious safety alert, typically reserved for risks that can result in death or life-threatening harm. The FDA label language for oxycodone explicitly states that concomitant use with benzodiazepines or other central nervous system (CNS) depressants "may result in profound sedation, respiratory depression, coma, and death."
The Substance Abuse and Mental Health Services Administration (SAMHSA) estimates that in 2020, approximately 11.7 million people misused prescription opioids in the United States. Among those, concurrent benzodiazepine use is documented in roughly 30–40% of patients on chronic opioid therapy, a pattern that significantly elevates overdose mortality risk. Between 2015 and 2019, the National Center for Health Statistics reported that opioid overdose deaths involving benzodiazepines increased by over 12% annually, with the majority of these deaths occurring in patients taking both drug classes as prescribed—not through illicit use.
The FDA adverse event reporting system (FAERS) has logged over 6,000 serious adverse events and deaths associated with concurrent opioid and benzodiazepine use in the past decade alone. A 2019 study published in JAMA Psychiatry found that patients receiving concurrent opioid and benzodiazepine prescriptions had a 50-fold higher risk of opioid-involved overdose death compared to those on opioids alone.
The oxycodone-benzodiazepine interaction is rooted in how both drugs affect the central nervous system. Oxycodone is a mu (μ) opioid receptor agonist that binds to opioid receptors in the brain and spinal cord, decreasing pain signal transmission and producing sedation, euphoria, and respiratory depression. Benzodiazepines (such as alprazolam, lorazepam, and diazepam) are positive allosteric modulators of GABA-A receptors, meaning they enhance the inhibitory effects of GABA neurotransmission, leading to sedation, muscle relaxation, and anxiolysis.
The critical danger lies in synergistic CNS depression. When oxycodone and benzodiazepines are taken together, they do not simply add their effects—they amplify each other. At the level of the medullary respiratory center (the brain region controlling breathing), both drugs suppress the drive to breathe. Oxycodone does this by activating mu-2 opioid receptors that inhibit dopaminergic and noradrenergic neurons involved in respiration. Benzodiazepines increase GABAergic tone, which also dampens respiratory neurons. This dual suppression can result in hypoventilation (shallow or slowed breathing), hypoxemia (low blood oxygen), and ultimately respiratory arrest.
Additionally, both oxycodone and benzodiazepines undergo hepatic metabolism, though generally via different cytochrome P450 pathways. Oxycodone is metabolized primarily by CYP3A4 and CYP2D6, while most benzodiazepines (alprazolam, triazolam) are metabolized by CYP3A4 and CYP2C19. This means there is potential for minor metabolic competition, which could modestly elevate oxycodone levels—but the primary danger is the pharmacodynamic (functional) interaction at the receptor level, not metabolism.
At lower doses, patients may experience profound drowsiness, confusion, and impaired cognition. At higher doses or with rapid escalation, respiratory depression becomes life-threatening within minutes to hours. The risk is particularly acute because both drugs have long half-lives (oxycodone: 3–4.5 hours; alprazolam: 6–12 hours; diazepam: 20–70 hours), meaning accumulation over days increases baseline risk even if each individual dose seems tolerable.
Certain patient populations face disproportionate risk from oxycodone-benzodiazepine combinations:
A 52-year-old woman with generalized anxiety disorder undergoes knee arthroscopy. Her primary care physician prescribes oxycodone 5 mg every 6 hours as needed for postoperative pain. She is already taking alprazolam 0.5 mg twice daily for anxiety, a regimen she has been on for 3 years. On postoperative day 2, she takes oxycodone 5 mg at 2 PM and then takes her scheduled alprazolam dose at 4 PM. By 6 PM, her partner finds her nearly unresponsive, with slow and shallow breathing (8 breaths per minute). Emergency services are called; she is given naloxone (Narcan) and admitted to the ICU, where she requires mechanical ventilation for 18 hours.
This scenario illustrates how prescription-as-directed use can still result in overdose when the prescriber and patient are unaware of the interaction. The woman's surgeon did not communicate with her primary care doctor about her alprazolam use. At discharge, she was not counseled about the risks of combining these drugs or told to space doses or reduce either medication. The interaction was entirely preventable.
A 67-year-old man with chronic low back pain and insomnia has been on oxycodone 10 mg three times daily for 8 years. His pain is reasonably controlled. However, he develops worsening anxiety, and his psychiatrist prescribes diazepam 5 mg at bedtime "to help with sleep and anxiety." The psychiatrist, reviewing the medication list, sees "oxycodone" but may not fully appreciate the interaction risk if communication between prescribers is poor. The man reports improved sleep for the first week. By week 3, his daughter notices he is increasingly drowsy during the day, has difficulty staying awake during conversations, and his breathing sounds "labored" at night. She brings him to the emergency department, where arterial blood gas analysis shows CO2 retention (hypercapnia) and low oxygen saturation (88%), confirming ventilatory failure. He is treated with continuous positive airway pressure (CPAP) and admitted for monitoring.
This scenario highlights the risk in chronic polypharmacy where patients see multiple specialists who may not coordinate. The cumulative effect of long-term oxycodone exposure plus a newly added benzodiazepine can be overlooked, especially if the patient has been "stable" on opioids for years—tolerance develops to pain relief and euphoria, but not to respiratory depression.
If you are currently taking both oxycodone and a benzodiazepine (or any opioid and any benzodiazepine):
Seek emergency help (call 911 in the U.S.) if you or someone else on this combination experiences:
Call your doctor or poison control (1-800-222-1222 in the U.S.) if you notice:
If you are on oxycodone and a benzodiazepine, be alert to other medication combinations that can amplify risk. Oxycodone and alcohol together dramatically increase overdose risk. Oxycodone and gabapentin may also elevate CNS depression. Similarly, benzodiazepines and alcohol are a dangerous mix on their own. Always inform your pharmacist of your complete medication list, including over-the-counter drugs and supplements.
Your medication safety depends on clear communication. Check your complete drug interaction profile right now at checkdruginteractions.com. Our comprehensive database, built from over 250,000 FDA drug labels, will flag every interaction between your medications and help you and your pharmacist make informed, safer decisions. Enter all your prescriptions, over-the-counter drugs, and supplements—it takes just a few minutes and could save your life.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Tacrolimus and fluconazole interaction explained. Learn severity, risks, and what FDA labels say about combining these drugs.
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.